Le Lézard
Classified in: Health, Science and technology, Business
Subjects: BFA, FVT

Caris Life Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference


IRVING, Texas, Jan. 2, 2024 /PRNewswire/ -- Caris Life Sciences® (Caris), the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced today that the company will present at the 42nd Annual J.P. Morgan Healthcare Conference, which is being held January 8-11, 2024 in San Francisco.

Caris Life Sciences executives will provide an overview of the business and discuss recent corporate achievements

Caris will present at 11:00 a.m. PST on Tuesday, January 9, and will provide an overview of the business and discuss recent corporate achievements that position the organization to further extend its leadership position in the market.

Caris will be represented by:

About Caris Life Sciences
Caris Life Sciences® (Caris) is the leading next-generation AI TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

Headquartered in Irving, Texas, Caris has offices in Phoenix, New York, Tokyo, Japan and Basel, Switzerland. Caris or its distributor partners provide services in the U.S., Europe, Asia and other international markets. To learn more, please visit CarisLifeSciences.com.

Investor Relations Contact:
Argot Partners
[email protected]
212.600.1902

Media Contact: 
Lisa Burgner
Caris Life Sciences
[email protected]
214.294.5606

SOURCE Caris Life Sciences


These press releases may also interest you

at 20:30
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech , today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for the treatment of adult...

at 20:05
Telix Completes Proof-of-Concept Study of TLX592 Targeted Alpha Therapy in Prostate Cancer
CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer.Establishes proof-of-concept for Telix's proprietary RADmAb® engineered antibody platform, currently under...

at 19:42
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST. Right to...

at 18:54
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today,...

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

More news about Health...


News published on and distributed by: